Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions

In this article we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.

Recent Content

A new analysis of the exome of primary bladder cancer has found a relatively frequent mutation in a gene called BAP1 (BRCA1 associated protein-1).

A new oral tablet formulation of olaparib, a PARP inhibitor (poly (ADP-ribose) polymerase), is safe when combined with chemotherapy in advanced ovarian cancer patients previously treated with other agents.

Recent findings from a phase II randomized clinical trial demonstrates that a breast cancer vaccine known as GP2, may help at preventing disease recurrence in women with HER2 protein overexpression.

She came in with her husband for a consultation, and to receive information on potential clinical trials.

Immunotherapies, such as anti-PD-1 and anti-PD-L1 antibodies, offer promising new treatment options for various malignancies including non-small cell lung cancer (NSCLC). With the advent of these immunotherapies, much interest and energy has been focused on developing a companion predictive biomarker

Screening for genes that head and neck squamous cell carcinomas (HNSCC) need to survive, researchers have identified a potential new drug for the disease that will enter clinical trials later this year.

Many of the new treatment options for melanoma are very exciting as evidence of cancer advancement through science and clinical trials. However, we are still gathering post-market data on its associated side effects.

By clicking Accept, you agree to become a member of the UBM Medica Community.